<DOC>
	<DOCNO>NCT02345226</DOCNO>
	<brief_summary>This study evaluate efficacy safety emtricitabine/rilpivirine/tenofovir alafenamide ( FTC/RPV/TAF ) fix dose combination ( FDC ) versus continue efavirenz/emtricitabine/tenofovir disoproxil fumarate ( EFV/FTC/TDF ) FDC HIV-1 infect adult virologically suppress ( HIV 1 RNA &lt; 50 copies/mL ) stable regimen EFV/FTC/TDF FDC ≥ 6 consecutive month screen .</brief_summary>
	<brief_title>Study Evaluate Switching From Regimen Consisting Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate ( EFV/FTC/TDF ) Fixed Dose Combination ( FDC ) Emtricitabine/Rilpivirine/Tenofovir Alafenamide ( FTC/RPV/TAF ) FDC Virologically-Suppressed , HIV-1 Infected Adults</brief_title>
	<detailed_description />
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Rilpivirine</mesh_term>
	<mesh_term>Efavirenz , Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Key The ability understand sign write informed consent form , must obtain prior initiation study procedure Currently receive EFV/FTC/TDF FDC 6 consecutive month precede screen visit Documented plasma HIV1 RNA level &lt; 50 copies/mL ( undetectable HIV1 RNA level accord local assay use limit detection &gt; 50 copies/mL ) 6 month precede screen visit . Unconfirmed virologic elevation ≥ 50 copies/mL previously reach viral suppression ( transient detectable viremia , `` blip '' ) prior screen acceptable Have document resistance study agent time past HIV1 RNA &lt; 50 copies/mL screen visit Hepatic transaminase ( AST ALT ) ≤ 5 × upper limit normal ( ULN ) Total bilirubin ≤ 1.5 mg/dL , normal direct bilirubin Adequate hematologic function ( absolute neutrophil count ≥ 1,000/mm^3 ; platelet ≥50,000/mm^3 ; hemoglobin ≥ 8.5 g/dL ) Serum amylase ≤ 5 × ULN ( individual serum amylase &gt; 5 × ULN remain eligible serum lipase ≤ 5 × ULN ) Normal ECG ( abnormal , determined Investigator clinically significant ) Adequate renal function : Estimated glomerular filtration rate ≥ 50 mL/min accord CockcroftGault formula Key Hepatitis B surface antigen ( HBsAg ) positive Hepatitis C antibody positive detectable hepatitis C virus ( HCV ) RNA ( individual HCV antibody detectable HCV RNA eligible enroll ) Individuals experience medical history decompensated cirrhosis ( e.g. , ascites , encephalopathy , etc . ) Females breastfeed Positive serum pregnancy test Current alcohol substance use judge Investigator potentially interfere individual 's study compliance A history malignancy within past 5 year ( prior screen ) ongoing malignancy cutaneous Kaposi 's sarcoma ( KS ) , basal cell carcinoma , resect , noninvasive cutaneous squamous carcinoma . Individuals cutaneous KS eligible , must receive systemic therapy KS within 30 day Baseline/Day 1 must anticipate require systemic therapy study Active , serious infection ( HIV1 infection ) require parenteral antibiotic antifungal therapy within 30 day prior Baseline/Day 1 Any clinical condition prior therapy , opinion Investigator , would make individual unsuitable study unable comply dose requirement Participation clinical trial ( include observational trial ) without prior approval sponsor prohibit participate trial Individuals receive ongoing therapy follow medication table , include drug use FTC , RPV and/or TAF ( refer individual agent Prescribing Information ) ; individual know allergy excipients FTC/RPV/TAF Note : Other protocol define inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>HIV</keyword>
</DOC>